VANGL2 regulates luminal epithelial organization and cell turnover in the mammary gland

Prestina Smith1, Nathan Godde2,3,4, Stefany Rubio1, Melawit Tekeste1, Eszter K. Vladar5,6, Jeffrey D. Axelrod5, Deborah J. Henderson7, Michal Milgrom-Hoffman8, Patrick O. Humbert2,3,8,9,10 & Lindsay Hinck1

The VANGL family of planar cell polarity proteins is implicated in breast cancer however its function in mammary gland biology is unknown. Here, we utilized a panel of Vang1 and Vangl2 mouse alleles to examine the requirement of VANGL family members in the murine mammary gland. We show that Vang1CKOΔ/Δ glands display normal branching while Vangl2floxfloxfloxflox and Vangl2LpLp tissue exhibit several phenotypes. In MMTV-Cre;Vangl2floxflox glands, cell turnover is reduced and lumens are narrowed. A Vangl2 missense mutation in the Vangl2LpLp tissue leads to mammary anlage sprouting defects and deficient outgrowth with transplantation of anlage or secondary tissue fragments. In successful Vangl2LpLp outgrowths, three morphological phenotypes are observed: distended ducts, supernumerary end buds, and ectopic acini. Layer specific defects are observed with loss of Vangl2 selectively in either basal or luminal layers of mammary cysts. Loss in the basal compartment inhibits cyst formation, but has the opposite effect in the luminal compartment. Candidate gene analysis on MMTV-Cre;Vangl2floxflox and Vangl2LpLp tissue reveals a significant reduction in Bmi1 expression, with overexpression of Bmi1 rescuing defects in Vangl2 knockdown cysts. Our results demonstrate that VANGL2 is necessary for normal mammary gland development and indicate differential functional requirements in basal versus luminal mammary compartments.

Recent studies have implicated the planar cell polarity (PCP) genes VANGL1 and VANGL2 in breast cancer1. A high level of VANGL1 expression is associated with poor prognosis and relapse in breast cancer patients2. Similarly, upregulation of VANGL2 was identified in the more aggressive basal type tumors and is also associated with poor prognosis3. While alterations of VANGL1 and VANGL2 in breast cancer have been investigated, their function in normal breast development is still unknown. Here we provide the first analysis of VANGL function in mammary gland development in vivo.

The mammary gland is a branched organ with epithelial ducts that grow outward from the nipple into a surrounding fat pad. These ducts are bi-layered structures, composed of an outer basal layer of contractile myoepithelial cells and an inner luminal layer of secretory cells. Mammary identity is established early in the developing embryo. By E11.5, FGF and WNT signals drive cell fate specification in order to produce the first mammary epithelium4. This group of cells further expands around E15.5 to form a mammary bud. At birth, the mammary gland exists as a rudimentary tree with few branches and a hollow lumen. The mammary gland then remains quiescent until puberty when it undergoes massive growth by branching. During branching morphogenesis, end...
buds (EBs) establish the mammary tree through two types of branching. Initially, a small number of terminal EBs (TEBs) sprout into the fat pad and, through coordinated migration and bifurcation events, produce primary branches that extend from the nipple to the outer edges of the fat pad. Next, lateral end buds form on the sides of primary branches and sprout secondary and tertiary branches. The formation and expansion of EBs in the mammary gland relies on the precise deployment of extracellular signals. One of the major drivers of mammary gland morphogenesis is WNT signaling.

WNT signaling can be divided into canonical and non-canonical pathways. Canonical WNT signaling has been implicated in multiple aspects of mammary gland development, however, details regarding non-canonical WNT signaling in the mammary gland remain elusive. The non-canonical WNT/Planar cell polarity (PCP) signaling axis propagates directional information across sheets of epithelium. At the core of PCP signaling is the Van Gogh Like (VANGL) family of transmembrane proteins: VANGL1 and VANGL2. One of the VANGL family proteins, VANGL2, is required for proper branching and tubulogenesis of the kidney and lung, but the exact mechanism of this action is unknown.

To examine the requirement of VANGL family members in the murine mammary gland, we utilized a panel of Vangl1 and Vangl2 mouse alleles. Here, we report that Vangl2 missense and loss-of-function mutations stunt mammary gland development whereas a Vangl1 hypomorphic mutation does not affect mammary outgrowth or branching morphogenesis. In addition, using different Vangl2 alleles, we demonstrate that loss of cell surface VANGL2 results in different phenotypes compared to Vangl2 deletion. Using in vitro primary cultures, we show that VANGL2 has distinct functions in the basal and luminal cell compartments. Finally, we show that loss of Vangl2 lowers expression of the polycomb group repressor Bmi1 and hinders cyst formation, while overexpression of the gene rescues cyst formation in vitro. Our studies provide insight into mechanisms that control growth and development in the mammary gland and show a novel mechanism for PCP signaling in influencing transcriptional repressors. Our studies also further broaden the scope of non-canonical WNT signaling in the mammary gland and draw useful comparisons between different Vangl loss-of-function models.

### Results

**Vangl2 is expressed in multiple cell populations in the mammary gland.** To establish the role of PCP genes Vangl1 and Vangl2 in the mammary gland, we initially examined their mRNA levels using RT-qPCR. Cells isolated from mammary glands harvested from adult wildtype (WT) mice were FACS purified into three subpopulations: basal (Lin-CD24^+CD29^hi), mature luminal (Lin-CD24^loCD29^-CD61^-), and luminal progenitor (Lin-CD24^loCD29^+CD61^+). RNA isolated from each cell type was subjected to RT-qPCR using primers specific to Vangl1 and Vangl2. Results from these experiments show Vangl1 and Vangl2 expressed in all mammary cell populations (Fig. 1A). Re-analysis of a previously published GEO dataset (GSE19446) that profiled FACS sorted normal mouse mammary cell subpopulations independently supported this observation (Supp. Fig. 1).
Previous studies have linked the function of VANGL1 and VANGL2 to their subcellular localization, and their role in PCP is characterized by their membrane localization at the apical epithelial cell junctions and within recycling endosomes. In order to better understand these proteins in the mammary gland, we investigated the subcellular localization of the VANGL proteins by immunohistochemical analysis of sectioned mammary glands from mature virgin mice stained with antibodies generated against VANGL1, VANGL2, and basal lineage markers K14 and SMA. Consistent with the mRNA expression, VANGL1 and VANGL2 were expressed in all luminal cells and approximately 70% of basal cells (Fig. 1B). Within each cell, VANGL1 and VANGL2 were found both at the membrane, consistent with their role in cell/cell interactions, and in a punctate pattern within the cytoplasm, consistent with their active regulation by endocytosis (Fig. 1CD).

Previous studies have shown the importance of graded VANGL2 expression during tissue morphogenesis. To further investigate the role of VANGL2 in the adult mammary gland, we quantified protein levels across the gland. To this end, we harvested mammary glands from WT mature virgin mice, cut the tissue into the proximal (near nipple, P), central (C) and distal (TEB-containing, D) regions and used protein isolated from each region for immunoblotting with antibodies against VANGL2, K18 (luminal cells) and GAPDH (loading control). We found VANGL2 present in a gradient from the nipple to the TEBs, with a 5-fold VANGL2 increase in the central and a 15-fold increase in the distal, compared to the proximal, regions (Fig. 1E,F, Supp. Fig. 4). To examine VANGL2 subcellular localization in distal TEBs, where it is more concentrated, we micro-dissected them and immunostained with anti-VANGL2 antibodies. We observed VANGL2 staining in a punctate pattern in the cytoplasm and at the membrane in the unpolarized luminal cells (body cells) that constitute the body of the end bud (Fig. 1G), suggesting a role for VANGL2 in TEBs during ductal morphogenesis. Taken together, these results show both VANGL1 and VANGL2 are expressed in mammary epithelial cells and suggest a role for the proteins in the development of the mammary gland.

Vangl1 is dispensable for normal mammary morphogenesis. VANGL1 and VANGL2 are transmembrane proteins that rely on cell surface expression to carry out PCP signaling. In order to investigate the role of VANGL1 and VANGL2 in the mammary gland, we examined the loss-of-function phenotypes of these proteins using mice carrying mutations that disrupt trafficking of the proteins to the cell surface. The previously described Vangl1Cre mice were generated by using the HRPT-Cre allele to delete all of the transmembrane domains of Vangl1 in the germline. Consequently, these homozygous deleted mice (Vangl1CreΔ/Δ) produce a VANGL1 protein that is improperly trafficked to the membrane, disrupting the function of VANGL1 in PCP. To investigate the overall structure of Vangl1CreΔ/Δ mammary glands, we carmine stained whole mounted glands from mature virgin mice and observed a fully expanded mammary epithelial tree, characterized by ducts reaching the outer edges of the fat pad in a growth pattern similar to WT (Fig. 2A). We performed branching analysis to assay TEB bifurcation (primary branching) and secondary/tertiary branching and discovered no significant difference between WT and Vangl1CreΔ/Δ tissue (Fig. 2B–D). We further investigated the role of VANGL1 in mammary morphogenesis by examining cell morphology in Vangl1CreΔ/Δ glands. To confirm mislocalization of VANGL1, we immunostained with anti-VANGL1 and observed an increase in puncta localized in the cytoplasm of Vangl1CreΔ/Δ tissue (Fig. 2E). This observation was consistent with a previously described trafficking defect15. Additionally, we immunostained with anti-Cdh1 and observed a normal epithelial staining pattern in both WT and Vangl1CreΔ/Δ tissue, with E-cadherin localized to cell junctions (Fig. 2E). Together, these data suggest that VANGL1 signaling at the plasma membrane is dispensable in mammary development.

Loss of Vangl2 impairs cell turnover and generates compacted ducts with narrow lumens. To investigate the consequences of Vangl2 deletion in the mammary gland in the context of normal Vangl1 expression, we utilized a previously developed floxed allele of Vangl2 consisting of loxP sites flanking exon 417. Expression of Cre in these mice introduces a premature stop codon and subsequent loss of all four transmembrane domains of Vangl2 in the germline. Consequently, these homozygous deleted mice (Vangl2flx/Δ) produce a VANGL2 protein that is improperly trafficked to the membrane, disrupting the function of VANGL2 in PCP. To specifically delete Vangl2 in the mammary epithelium, we crossed these mice with MMTV-Cre transgenic mice that delete floxed genes in both luminal and basal mammary epithelial cells. We then confirmed dose dependent loss of Vangl2, but not Vangl1, in the mammary glands of MMTV-Cre;Vangl2flx/Δ and MMTV-Cre;Vangl2flx/Δ mice by RT-qPCR (Fig. 3A). To assess the developmental impact of VANGL2 loss on branching, we examined whole mount preparations of inguinal mammary glands from mature virgin mice. We observed no change in branch number or ductal extension (Fig. 3B). Next we performed histological analysis on H&E stained mammary gland sections from MMTV-Cre, MMTV-Cre;Vangl2flx/Δ, and MMTV-Cre;Vangl2flx/Δ mice. We found that MMTV-Cre;Vangl2flx/Δ glands contained significantly narrower ducts, as measure by luminal width, than MMTV-Cre;Vangl2flx/Δ or MMTV-Cre controls (Fig. 3C) ($p < 0.03$). These results suggest a pronounced defect in duct widening characterized by a near absence of luminal space in the absence of VANGL2.

To determine if changes in cellular size or composition are associated with narrowed ducts, we performed immunostaining using luminal (K8) and basal (K5, SMA) differentiation markers. These analyses found that although Vangl2-deficient ducts were narrow, they retained a normal bilayered epithelium consisting of single layers of luminal and basal cells of a similar size and shape to normal control cells (Fig. 3D). The maturation and proper formation of the mammary epithelium is characterized by the specification of distinct apical and basolateral membrane identities. Because VANGL2 is a key cell polarity gene, we next examined the polarization of apical membrane domains and formation of basolateral adherence junctions in these narrow ducts. We observed intact expression of E-cadherin (anti-Cdh1) along cell-cell boundaries and apical expression of phosphor-ezrin/radixin/moesin (anti-pERM) along all cell membranes exposed to luminal space (Fig. 3E). Altogether these studies suggest that Vangl2-deficient cells are capable of differentiating and responding to key polarization cues during ductal morphogenesis despite abnormal ductal morphogenesis.
We next investigated whether the narrowed ducts were a result of changes in proliferation and/or apoptosis by performing Ki67 and Cleaved Caspase 3 immunohistochemistry on mature virgin MMTV\textsuperscript{-}Cre;Vanglflox/+ and MMTV\textsuperscript{-}Cre;Vanglflox/flox glands. We detected significantly lower rates of both proliferation and apoptosis in Vangl2-deficient mammary epithelium compared to control (Fig. 3F, G). These findings support previous work suggesting that cell turnover mediated by mitogenic signaling and pro-apoptotic factors, such as BCL2L11 (BIM), is an essential process for proper lumen formation and maintenance in the mammary gland\cite{20}. During ductal morphogenesis, we also detected lower proliferation within the ducts, but not TEBs, of 6 weeks old mice (Supp. Fig. 2A). Taken together, these results suggest that VANGL2 plays a specific role in mammary duct homeostasis, not in cell differentiation or duct elongation, but specifically in duct maturation and lumen expansion, and the defects observed in the absence of VANGL2 may result from inappropriate cell turnover and proliferation.

Deregulation of VANGL2 function stunts mammary outgrowth. Next, we investigated disruption of both Vangl1 and Vangl2 by examining the well-characterized Looptail (Vangl2 Lp/Lp) mice, which harbor a missense mutation in the Vangl2 gene that interrupts both VANGL1 and VANGL2 trafficking to the cell surface\cite{21,22}. This mutation results in severe PCP defects in multiple organs, leading to embryonic lethality\cite{23}. To study the mammary gland, which develops postnatally, we followed standard protocols to generate Vangl2 Lp/Lp mammary outgrowths via anlage rescue\cite{24}. This entailed harvesting E16.5 mammary anlage from Vangl2Lp/Lp and WT embryos and contralaterally transplanting them into adult hosts that had been pre-cleared of endogenous mammary epithelium. To determine if VANGL1 was altered in the Vangl2 Lp/Lp mammary epithelium, we immunostained sectioned WT and Vangl2Lp/Lp tissue with anti-VANGL1 and found reduced levels of VANGL1, especially along the cell borders in the luminal compartment, in the mutant compared to WT (Supp. Fig. 2B). Whole mount analysis of tissue harvested 12-weeks post-transplantation showed that tissue transplanted from Vangl2 Lp/Lp embryos generated fewer outgrowths compared to WT (Fig. 4A). To quantify, we defined no outgrowth as fat pads having less than 10% of their area filled with epithelium. Our analysis found that 32% (7/22) of fat pads transplanted with Vangl2 Lp/Lp anlage had outgrowths compared to 60% (18/30) of WT (Fig. 4B). To address whether this phenotype was due to transplantation of embryonic tissue, we performed a secondary transplant by harvesting a tissue fragment from each of the 7 mature Vangl2 Lp/Lp and 5 mature WT outgrowths and transplanting it into a new host fat pad. We again observed deficient transplantability of Vangl2 Lp/Lp tissue. In this experiment, 44% (20/45) of fat pads containing Vangl2 Lp/Lp transplants generated an outgrowth compared to 93%
Figure 3. Deletion of Vangl2, but not Vangl1, in the mammary gland results in narrow ducts and low cell turnover. (A) RT-qPCR analysis of Vangl1 and Vangl2 mRNA levels in the mammary glands of MMTV-Cre, MMTV-Cre;Vangl2flx/+, and MMTV-Cre;Vangl2flx/flx at 10 weeks of age. (B) Representative images of 10 week old, carmine stained mammary glands and quantification of total branch number from MMTV-Cre, MMTV-Cre;Vangl2flx/+, and MMTV-Cre;Vangl2flx/flx mice (n = 3 mice per genotype). (C) Histological analysis by H&E staining show normal duct formation in 10 week old MMTV-Cre and MMTV-Cre;Vangl2flx/+ glands, whereas ducts from MMTV-Cre;Vangl2flx/flx glands are narrow and have significantly diminished lumens (n = 3 mice/genotype). (D) Immunostaining in mammary ducts show normal distribution of luminal (Cytokeratin 8 (K8), green), and basal (K5), red; SMA magenta) cell populations. (E) Immunofluorescence of adhesion junctional protein E-Cadherin (CDH1, green) and apical membrane marker pERM (red). (F,G) Immunostaining in 10 week old MMTV-Cre;Vangl2flx/+ and MMTV-Cre;Vangl2flx/flx glands and quantitation of (F) Ki67 and (G) Cleaved Caspase 3 (n = 3–5 mice per genotype). Lu indicates lumen. * indicates non-magnified duct. Data are represented as mean ± SEM. Scale bar represents 100 μm (C,F,G) 50 μm (D) and 10 μm (E). Student’s t-test *p < 0.05 and ****p < 0.0001.
(42/45) of those transplanted with WT (Fig. 4B). These data suggest that the effect of VANGL2 signaling on outgrowth potential persists from embryonic to adult tissue and could be influencing the stem cell population that drives embryonic and postnatal growth.

Given that stem cells, residing in the basal layer, drive outgrowth in the mammary gland and that our results show expression of VANGL2 in basal cells and stunted growth in Vanl2Lp/Lp outgrowths, we investigated the role of VANGL2 in stem cell self-renewal activity. Adult stem cells in the mammary gland are responsible for fueling postnatal growth of the gland. Previous studies have shown that mammary stem cell self-renewal can be assayed by serial transplantation whereby stem cells are challenged with growing an entire gland after each passage of a tissue fragment\(^{25,26}\). To this end, we serially transplanted contralateral WT and Vanl2Lp/Lp outgrowths and found they lost regenerative capacity at generation 4 and 5, respectively, suggesting that VANGL2 does not significantly alter tissue passageability. However, consistent with our previous data, WT tissue transplants generated 1.5 times more positive outgrowths in the first two passages compared to Vanl2Lp/Lp (Fig. 4C). Taken together, these data suggest that loss of cell surface VANGL proteins significantly reduces the outgrowth potential, but not the self-renewal capacity, of stem cells.

**Vanl2Lp/Lp embryos contain either stunted anlage or anlage containing supernumerary embryonic sprouts.** The large percentage of Vanl2Lp/Lp anlage rescue experiments that did not produce...
Vangl2Lp/Lp outgrowths display supernumerary end buds and ectopic acini. Given that TEBs are the site of growth and proliferation in the mammary gland and Vangl2Lp/Lp are expressed in this region, we performed additional transplantation experiments to evaluate the postnatal consequences of Vangl2Lp/Lp loss-of-function in successful mammary outgrowths. We observed three distinct phenotypes in Vangl2Lp/Lp outgrowths (n = 20 WT/LP pairs) that were non-mutually exclusive. One phenotype was an abundance of end buds. We found that 45% (9/20) of Vangl2Lp/Lp outgrowths contained 6-fold more TEBs that were significantly larger compared to WT (Fig. 5A–C,I, Supp. Fig. 2C). Together, these findings suggest that Vangl2Lp/Lp is expressed in a gradient across the gland and loss of this graded expression enhances TEB formation.

A second phenotype (8/20) was the formation of premature acini (Fig. 5D,E,I). Our transplantation assays were performed such that WT fragments were contralaterally transplanted into the same mouse as Vangl2Lp/Lp tissue. Therefore, both tissues were exposed to the same hormonal environment so this defect does not represent cyclic side branching. Nevertheless, we found that Vangl2Lp/Lp outgrowths contained twice as many acini per duct, compared to WT (Fig. 5D,E,I, Supp. Fig. 2D). To evaluate the morphology of these structures, we sectioned WT and Vangl2Lp/Lp tissue and immunostained with anti-CDH1, revealing a single layer of luminal cells surrounding a hollow lumen (Supp. Fig. 2E). In contrast, multiple layers of disorganized luminal cells frequently occluded Vangl2Lp/Lp acini (Supp. Fig. 2E). Thus, WT acini morphologically mimicked normal tertiary branching, whereas Vangl2Lp/Lp acini showed exuberant, disorganized, tertiary acini, despite being exposed to the same hormonal environment.

A third phenotype (6/20) was the presence of dilated ducts (Fig. 5G–I, Supp. Fig. 2F). We quantified the size of these ducts along their length by optically dividing each duct into horizontal sections using a grid and found that the average area of Vangl2Lp/Lp ducts was 3 times greater than WT (Fig. 5G). In addition to their increased size, Vangl2Lp/Lp ducts are also marked by pronounced constrictions along their lengths, giving the ducts a pinched appearance (Fig. 5H). In contrast, WT ducts are uniform in size; even if their area is expanding or contracting, the change is gradual (Fig. 5H). This difference was reflected in the quantification where we observed WT measurements clustering around 20 a.u., whereas Vangl2Lp/Lp measurements were more variable, echoing the abrupt changes in ductal size occurring over the length of Vangl2Lp/Lp ducts (Fig. 5G,H). Actin polymerization plays an important role in regulating lumen formation, and disorganized actin patterns have been observed in tubular and ductal organs of Vangl2Lp/Lp animals7–9. To evaluate the filamentous actin cytoskeleton, we sectioned and phalloidin stained WT and Vangl2Lp/Lp tissue, observing irregular f-actin organization and reduced staining, particularly in the luminal compartment of Vangl2Lp/Lp ducts (Supp. Fig. 2G). In order to investigate whether this phenotype was due to a loss in PCP signaling, we examined the morphology of mammary glands from another PCP mutant mouse, Prickle2 (Pk2). Pk2 is a cytoplasmic mediator of PCP signaling downstream of VANGL227. Immunostaining of sectioned glands obtained from mature virgin mice with anti–PK2 antibodies revealed cytoplasmic and membrane staining in a pattern similar to Vangl2Lp/Lp expression (Supp. Fig. 2H). Pk2 mutant mice have an embryonic lethal phenotype, resulting in termination around E3.5 before the mammary rudiment is formed28. This prevented anlage rescue; therefore instead, we harvested mammary glands from adult virgin WT and Pk2−/− mice and performed whole mount analysis. Similar to WT, we found that Pk2−/− glands filled 100% of the fat pad (Supp. Fig. 2I), but Pk2−/− ducts were dilated except for constrictions, a phenotype also observed in Vangl2Lp/Lp outgrowths (Fig. 5G,H). Taken together these results suggest that loss of surface VANGL signaling regulates mammary ductal diameter.

Depletion of VANGL2 in basal versus luminal cell populations alters cyst formation. Expression of Vangl2Lp/Lp in both the luminal and basal subpopulations, and the range of phenotypes displayed in Vangl2Lp/Lp outgrowths, suggest that Vangl2Lp/Lp is governing different aspects of mammary gland development, perhaps by differentially influencing cell interactions and signaling in the distinct basal and luminal compartments of the mammary gland. To test this hypothesis, we used differential trypsinization to separate the two subpopulations29 and lentiviral-mediated knock down to reduce expression of Vangl2 in either the basal, luminal or both cell types (Supp. Fig. 3A,B,4). By mixing knock down (KD) and WT subpopulations of cells and culturing them in Matrigel in the absence of growth factors, we generated mammary cysts that were mosaic in the expression of Vangl2Lp/Lp, such that either the basal or luminal compartment was Vangl2Lp/Lp-deficient (Fig. 6A). As a control, we...
also generated KD and WT cysts in which both or neither compartments were VANGL2-deficient (Fig. 6A). WT cells formed round cysts with approximately 3 protrusions, whereas KD cysts were half the size with no protrusions (Fig. 6B,C). KD of Vangl2 in the luminal layer produced cysts similar in overall appearance to WT but 3-fold larger (Fig. 6A,B). Consistent with this increase in size, the KD cysts had 2-fold more cell protrusions (Fig. 6A,C).

We immunostained these cysts with lineage markers K14 and K8 (Fig. 6D). Optical sections through these cysts show that, while WT cysts have clear lumens, Vangl2 luminal KD cysts contained a filled lumen. These data show that loss of VANGL2 in the luminal population leads to disorganization, which echoes the TEB and acinar phenotypes in the Vangl2Lp/Lp full outgrowths and the narrowed lumen phenotype in the MMTV-Cre;Vangl2flox/flox glands. In contrast, KD of Vangl2 in the basal layer, which contains a subpopulation of mammary stem cells, yielded cysts that resembled the full Vangl2 KD cysts: half the size of WT with half the number of protrusions.

Figure 5. Vangl2Lp/Lp outgrowths display distinct morphological defects. (A) Magnified view of supernumerary end buds in Vangl2Lp/Lp tissue from carmine stained, contralaterally transplanted WT and Vangl2Lp/Lp outgrowths 12 weeks post-transplantation; WT outgrowth contains no supernumerary end buds. Quantification of the area (B) and number (C) of end buds in WT and Vangl2Lp/Lp outgrowths. (D) Magnified view of acini in Vangl2Lp/Lp tissue from carmine stained, contralaterally transplanted Vangl2Lp/Lp tissue; WT outgrowth contains no acini. Arrow shows tertiary branching. Arrowhead denotes acinar structure. (E) Quantification of the number of acini in WT and Vangl2Lp/Lp outgrowths. (F) Magnified view of dilated ducts in tissue from carmine stained, contralaterally transplanted WT and Vangl2Lp/Lp outgrowths, harvested at 12 weeks; WT outgrowth shows smooth ductal borders with no constrictions. (G) Quantification of ductal size in WT, Vangl2Lp/Lp and Pk2+/− tissue (n = 10 ducts from 3 mice per genotype). (H) Representative images of carmine stained WT outgrowth, Vangl2Lp/Lp outgrowth and Pk2+/− ducts and displaying pinched ductal phenotype. Arrows denote constrictions. (I) Cartoon representation of the distinct phenotypes observed in Vangl2Lp/Lp outgrowths: DD, dilated ducts; SE, supernumerary end buds; A, acini. Scale bars represent 1.5 mm. Data are represented as mean ± SEM. Students t-test *p < 0.05, ***p < 0.001, and ****p < 0.0001.
The small size and number of these basal cysts prevented us from successfully immunostaining them. These studies suggest that VANGL2 has different functions in the luminal and basal compartments, restricting cyst formation in the luminal compartment while promoting cyst formation in the basal compartment.

Figure 6. Knockdown of Vangl2 in the basal versus luminal layers of cysts alter morphology. (A) Schematic (top) and representative images (bottom) of mosaic cysts after 4 days in culture. Quantification of cyst size (B) and number of protrusions (C) in the mosaic cysts. (D) Immunostaining of K14 (red) and K8 (green) showing the surface (top) or inside (bottom) of WT or mosaic cysts with Vangl2 knocked down in only luminal cells. Representative images (E) and quantification (F) of rescue of Vangl2 KD cyst size with overexpression of Bmi1. n = 3 biological replicates. Scale bars represent 20 μm. Data are represented as mean ± SEM. Students t-test *p < 0.05.
To further understand VANGL2 signaling in the mammary gland, we performed RT-qPCR on cDNA generated from Vangl2lox/lox and WT outgrowths and mammary tissue derived from MMTV-Cre;Vangl2lox/lox and MMTV-Cre only mice to evaluate the expression of genes encoding proteins that mediate the downstream signaling functions of VANGL2. To probe canonical Wnt signaling, we measured expression of Axin2. In addition, as previous studies have shown that VANGL2 is a regulator of SHH, we evaluated SHH signaling by measuring the expression of downstream effectors Bmi1 and Ptc1. Although we found no change in Axin2 or Ptc1 expression in Vangl2lox/lox outgrowths compared to WT (Supp. Fig. 3C), we did observe a decrease in both Axin2 and Ptc1 in MMTV-Cre;Vangl2lox/lox compared to MMTV-Cre only mice (Supp. Fig. 3D). Importantly, we observed a significant and consistent down regulation of Bmi1 in both Vangl2lox/lox outgrowths and MMTV-Cre;Vangl2lox/lox mammary tissue compared to respective WT controls (Supp. Fig. 3C,D). Bmi1 is part of the polycomb repressive complex 1 (PRC1) that maintains genes in a transcriptional repressive, quiescent state. Loss of its expression in Vangl2lox/lox tissue could explain our difficulty rescuing Vangl2lox/lox anlage, propagating the tissue in vivo and generating cysts with KD of Vangl2 in the basal, stem cell containing compartment of the mammary gland. To investigate, we overexpressed Bmi1 in Vangl2 KD cysts and found that reconstitution of Bmi1 expression rescued the formation of cysts that were the same size as those generated with scrambled shRNA (Fig. 6E,F). These results show an inverse relationship between Vangl2 and Bmi1 expression and suggest this may regulate the viability and outgrowth of mammmary cells.

Discussion

Although non-canonical Wnt signaling has been shown to have an important role in normal mammary gland development, the mechanisms underlying the process remain elusive. WNTs have both diverse and vast influences on mammary morphogenesis that can be explained by their ability to engage various receptors. In this study, we address non-canonical Wnt/PCP signaling by directly examining the consequences of aberrant VANGL2 receptor function. We found that both VANGL1 and VANGL2 are expressed in the mammary gland and can be detected by immunostaining in the same cell populations; however, their loss-of-function phenotypes are different. We discovered that VANGL2 plays a more important role in both embryonic and postnatal gland development compared to VANGL1. We also observed distinct VANGL2 phenotypes depending on the genetic approach we used. Conditional loss of VANGL2 during puberty in the MMTV-Cre approach we used. Conditional loss of VANGL2 during puberty in the MMTV-Cre;Vangl2lox/lox mammary glands display narrow ducts and are consistent with luminal width defects previously observed in Vangl2 mutant mice. For example, embryonic and adult airway lumen in the lungs of Vangl2lox/lox and Vangl2lox/lox mice, respectively, are absent or narrow, a phenotype that is reminiscent of the narrow lumens observed in MMTV-Cre;Vangl2lox/lox mammary glands (Fig. 3C). In contrast, dilated lumens are observed in both Podocin-Cre;Vangl2lox/lox and Vangl2lox/lox embryonic kidneys. Recent studies show that ODCs are significantly off axis in Vangl2lox/lox embryonic kidneys compared to WT, leading to wider lumens. Thirty percent of Vangl2lox/lox mammary glands display dilated ducts, with some containing points of marked narrowing (Fig. 5F–H). Thus, it is likely that VANGL2 controls ODCs during mammary morphogenesis, but confirmation will require analysis of cell divisions and movements that occur over a longer time frame in the postnatal mammary gland. In addition, a number of other mechanisms have been implicated in mammalian lumen size control including RhogTase regulated actomyosin contractility, a known downstream effector of PCP signaling activity, and fluid-driven lumen expansion. We did observe reduced proliferation in MMTV-Cre;Vangl2lox/lox mammary glands (Fig. 3F), which may contribute to abnormal duct formation in the context of aberrant ODCs. In support of these findings in vivo, a similar reduction in proliferation with Vangl2 deletion was previously reported in two basal breast cancer lines, and we observed that Vangl2 deficiency, specifically in basal cells, impairs the growth of the entire cyst (Fig. 6A–C).

The fact that we observed different ductal diameter phenotypes in the MMTV-Cre;Vangl2lox/lox mammary gland versus Vangl2lox/lox outgrowths may be due to the timing of VANGL2 inactivation in these different models, the nature of the mutation, or both. Conditional loss of Vangl2 was achieved using a Cre driver activated during puberty and, while it resulted in a major reduction in VANGL2 protein, this decrease occurred after birth. In contrast, the endogenous missense mutation in the Looptail version of VANGL2 influences both embryonic and postnatal development. In the embryonic neuroepithelium and regenerating adult muscle, VANGL2 governs the asymmetric cell division of stem/progenitor cells by OCD. In the mammary gland, VANGL2 is expressed in the stem cell-containing, basal cell population. Disruption of mammary stem cell self-renewal, expansion and/or cell fate acquisition during embryogenesis could alter the cellular dynamics of the developing gland and dramatically influence ductal morphogenesis in ways that are distinct from the loss of VANGL2 during puberty. Moreover, recent findings describe VANGL proteins functioning together in a heteromeric protein complex that prevents trafficking of Vangl1 to the cell surface in Vangl2lox/lox mice. Indeed, we observed such disruption of VANGL1 localization at the cell borders of Vangl2lox/lox tissue (Supp. Fig. 2B) This dual disruption can result in mislocalization of other PCP components such as Pk2, and lead to more dominant phenotypic traits. Thus, the cell surface loss of both VANGL2 and VANGL1 from conception is likely to adversely affect both CE and OCD, and may explain the 50% decline in outgrowth potential, and the dilated ducts and other morphological phenotypes displayed in the successful Vangl2lox/lox outgrowths compared to MMTV-Cre;Vangl2lox/lox mammary glands.
A surprising result from this study was the identification of a link between the expression of BMI1 and VANGL2. We show that loss of VANGL2 reduces BMI1 expression and that overexpression of BMI1 rescues mammary cyst formation. BMI1 is involved in the self-renewal and maintenance of stem cells 37,38, and BMI1 KO mice have mammary glands that are stunted similar to Vangl2<sup>Lp/Lp</sup> outgrowths 39. Furthermore, the stem cell-containing, basal cell population of the mammary gland expresses VANGL2 and previous studies have shown that VANGL2 is needed for symmetric expansion of stem cell division 34,35. Because the Loop tail (Vangl2<sup>2p/2p</sup>) mutation is lethal, we performed anlage rescue, and this gave us our first indication of a potential stem cell defect in Vangl2<sup>2p/2p</sup> tissue. Compared to WT, there was a 50% reduced rescue of Vangl2<sup>2p/2p</sup> anlage, and a similar reduction in tissue viability with subsequent fragment passage. We also observed this decreased viability in our cyst assay when we reduced the level of Vangl2 expression in basal cells. We performed an in vivo serial transplantation assay that did not, however, reveal a difference in the passageability of WT and Vangl2<sup>1p/1p</sup> tissue. Although this result suggests that stem cells are not adversely affected by the loss of cell surface VANGL2 in Vangl2<sup>2p/2p</sup> tissue, an alternate explanation is that rescued tissue contains sufficient functional VANGL2 to preserve, at least some, mammary stem cell viability. Dosage sensitivity of the Vangl2<sup>2p</sup> allele is well documented 39, and supported in this study by the phenotypic heterogeneity observed in the mammary outgrowths produced by rescued anlage. Thus, it is tempting to speculate that VANGL2 may promote the expansion and/or self-renewal of mammary stem cells in the embryo and loss of VANGL2 signaling results in the depletion of the stem cell pool. Current experiments are aimed at understanding if VANGL2 is regulating stem cell number in the mammary gland using the null allele. Furthermore, it will be interesting to determine whether such deregulation of mammary stem cell self-renewal, expansion and/or cell fate acquisition by VANGL2 may contribute to its cancer modulatory effects.

**Methods**

**Mouse strains.** Vangl2<sup>1p/1p</sup> mice were obtained from Jackson Laboratory. Vangl1<sup>cko</sup> and Pk2<sup>1+/−</sup> mice were generated as previously described 15,28. Vangl2<sup>Fl/fl</sup> mice were generated as previously described 18, and were crossed with Tg(MMTV-cre)1Mam (line A) provided by K Wagner 19. This research was both approved by and conducted in accordance with the guidelines set by the University of California, Santa Cruz animal care committee (IACUC) and the Peter MacCallum Cancer Centre Animal Experimental Ethics. The research was conducted in compliance with National Health and Medical Research Council (Australia) guidelines.

**Mammary gland transplantation.** Mammary anlage were dissected from Vangl2<sup>1p/1p</sup> embryos, and transplanted into pre-cleared fat pads of Foxn1<sup>imm</sup> mice 40. Contralateral outgrowths were harvested 12 weeks post-transplant and subjected to whole mount carmine staining. For serial studies, epithelial fragments were harvested and transplanted into a new host every 12 weeks.

**In vivo branch quantification.** Primary branches were defined as ducts extending from the site of transplantation and terminating in an end bud. Secondary and tertiary branches were defined as branches extending from primary ducts or secondary branches, respectively. Branch number was quantified by tracing the primary ductal structure and counting the number of primary ducts and secondary/tertiary branches in Fiji 41.

**Ductal size quantification.** To quantify the size of ducts in wholemounts, we measured the area of each duct in whole mount images using Fiji. A grid comprised of vertical lines spaced equidistant was laid on top of whole mount images. This provided a way to divide the ducts into equal sections. Next, single ducts were outlined and the space (area) occupied by that duct in each section was quantified. To quantify duct width at the histological level, all H&E stained duct cross-sections (24–51 ducts/mouse, 3 mice/group), were captured on a BX51-P Olympus Microscope and the maximum width of each duct measured using Metamorph Image Analysis software (Molecular Devices).

**Immunohistochemistry and Immunofluorescence.** IHC was performed as previously described with: Hoechst (AnaSpec, #AS-83218), anti-E-cad (Cell Signaling, #3195 S or BD biosciences, 610182), anti-VANGL2 (SCBT, #46561), anti-VANGL1 (R&D, #HPA02235), Ki67 (Novus, NB500-170), Cleaved Caspase 3 and pERM (Cell Signaling #9661, #3726), Phalloidin (Invitrogen, #A12381), aSMA (DAKO, #M0851), anti-K8 (Developmental Studies Hybridoma Bank, Troma-1), Cytokeratin 5 (Covance, #PRB-160P), and anti-K14 (Covance, #PRB-155P). Images were collected on a Leica SP5 confocal microscope. Brightfield imaging was performed on a Bioevro BZ-9000 Digital Microscope (Keyence) and confocal microscopy performed on a Nikon C2 Confocal, Leica SP5 confocal and Solamere Spinning Disk Confocal Microscope. 3-dimensional reconstructions were performed using Fiji or NIS-elements.

**RNA extraction and RT-qPCR.** Total RNA was isolated from MEC and LEC primary cell fractions (separated as described 29) or from FACS-purified basal (Lin_CD24 + CD29-high) and luminal (Lin_CD24 + CD29low) cells using TRIzol reagent (Invitrogen) and prepared as previously described 32. cDNA was prepared from 1 µg RNA using an iScript cDNA synthesis kit (Bio-Rad). RT-qPCR was performed in triplicate using LightCycler 480 SYBR Green I Master (Roche) and quantified using either Rotor Gene 6000 real-time PCR machine and software or Bio-Rad CFX Connect Real-Time System and CFX Manager software (Bio-Rad). Samples were normalised to GAPDH and expression levels calculated using the 2 − ΔΔCt method. Real-time primers listed in S1 Table. Results were normalized to that of Gapdh.

**Transduction of primary mammary epithelial cells.** Luminal and myoepithelial primary MECs were isolated by differential trypsinization as previously described 29. Next, transduction of primary MECs was performed as described previously 42. Single MECs were seeded at a density of 500,000 cells in a 24-well low-attachment plate and infected at an MOI of 30 with designated lentivirus in 800 µl of growth media. Cells were infected overnight for ~16 h and washed three times with PBS and re-plated.
Primary mouse mammary epithelial cell cyst assay. 3D cultures were generated using the “on top” Matrigel method as previously described. Briefly, transduced luminal and myoepithelial cells were trypsinized into a single cells suspension. The cells were then mixed in a 1:4 myoepithelial: luminal ratio and seeded at a final density of 25,000 cells on Matrigel-coated 8 well chamber slides. Cells were allowed to attach to the surface of the Matrigel for 30 mins at 37°C. A final volume of 10% Matrigel in growth media was added to the cells after attachment. Cells were imaged and analyzed for cyst formation after 72 hrs.

Western blot analysis. Cell or whole tissue lysates were prepared and analyzed by western blot as previously described. Luminescence was captured onto x-ray film or by the Biorad Gel Doc XR+ imaging system. Images were then quantified using Image Lab with band densitometry normalized to GAPDH.

Statistical analysis. Statistical analyses (Student's t-test and ANOVA) were conducted on Graphpad Prism. Significance is indicated as \(^*\ p < 0.05\, \,**\ p < 0.01\, \,**\!*\ p < 0.001\, \,**\!*\!*\!*\!*\ p < 0.0001\). Bars represent SEM.

Data Availability
The datasets generated during and/or analysed during the current study are available in the Gene Expression Omnibus (GEO) Reference ID: GSE19446.

References
1. Hatakeyama, J., Wald, J. H., Printsev, I., Ho, H. Y. & Carraway, K. 3rd Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer. Endoc Relat Cancer 21, 57, https://doi.org/10.1002/edrc.35 (2012).
2. Anastas, J. N. et al. A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression. Oncogene 31, 3606–3708, https://doi.org/10.1038/onc.2011.313 (2012).
3. Puvirajesinghe, T. M. et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun 7, 10318, https://doi.org/10.1038/ncomms10318 (2016).
4. Macías, H. et al. The planar cell polarity gene Vangl2 is required for mammalian kidney-branching morphogenesis and glomerular maturation. Hum Mol Genet 19, 4663–4676, https://doi.org/10.1093/hmg/ddq397 (2010).
5. Zhang, Y. & Levin, M. Left-right asymmetry in the chick embryo requires core planar cell polarity protein Vangl2. Dev Cell 20, 171–179, https://doi.org/10.1016/j.devcel.2010.08.031 (2014).
6. Devenport, D. The cell biology of planar cell polarity. J Cell Biol 171, 179–189, https://doi.org/10.1016/j.jcb.2006.03.050 (2014).
7. Yates, L. L. et al. The planar cell polarity gene Vangl2 is required for normal lung branching morphogenesis. Hum Mol Genet 19, 2251–2267, https://doi.org/10.1093/hmg/ddj104 (2010).
8. Babayeva, S., Zilber, Y. & Torban, E. Planar cell polarity pathway regulates actin rearrangement, cell shape, motility, and nephrin distribution in podocytes. Am J Physiol Renal Physiol 300, F549–560, https://doi.org/10.1152/ajprenal.00566.2009 (2011).
9. Rocque, B. L. et al. Deficiency of the planar cell polarity protein Vangl2 in podocytes affects glomerular morphogenesis and increases susceptibility to injury. J Am Soc Nephrol 26, 576–586, https://doi.org/10.1681/ASN.2010040340 (2015).
10. Kuminoto, K. et al. Disruption of Core Planar Cell Polarity Signaling Regulates the Early Tubule Morphogenesis but Is Not Cytosogenic. Curr Biol 27, 3120–3131 e3124, https://doi.org/10.1016/j.cub.2017.09.011 (2017).
11. Lim, E. et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 12, R21, https://doi.org/10.1186/bcr2560 (2010).
12. Devenport, D., Oristian, D., Heller, E. & Fuchs, E. Mitotic internalization of planar cell polarity proteins preserves tissue polarity. Nat Cell Biol 13, 983–992, https://doi.org/10.1038/ncll2284 (2011).
13. Li, S. et al. Identification of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 12, R21, https://doi.org/10.1186/bcr2560 (2010).
14. Gao, B. et al. Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell 20, 163–176, https://doi.org/10.1016/j.devcel.2011.01.001 (2011).
15. Vlada, E. K., Bayly, R. D., Sangoram, A. M., Scott, M. P. & Axelrod, J. D. Microtubules enable the planar cell polarity of airway cilia. Dev Cell 22, 2203–2212, https://doi.org/10.1016/j.devcel.2012.09.046 (2012).
16. Kibar, Z. et al. Identification of a new chemically induced allele (Lp(m1Jus)) at the loop-tail locus: morphological, histological, and genetic mapping. Genomics 72, 331–337, https://doi.org/10.1006/geno.2000.6493 (2001).
17. Kibar, Z. et al. Ltp, a mammalian homolog of Drosophila Strabismus/Van Gogh, is altered in the mouse neural tube mutant Loop-tail. Nat Genet 28, 251–255, https://doi.org/10.1038/ng1981 (2001).
18. Ramasbottom, S. A. et al. Vangl2-regulated polarisation of second heart field-derived cells is required for outflow tract lengthening during cardiac development. PLoS Genet 10, e1004871, https://doi.org/10.1371/journal.pgen.1004871 (2014).
19. Wagner, K. U. et al. Core-mediated gene deletion in the mammary gland. Nucleic Acids Res 35, 4323–4330 (1997).
20. Maileux, A. A., Overholtzer, M. & Brugge, J. S. Lumen formation during mammary epithelial morphogenesis: insights from in vitro and in vivo models. Cell Cycle 7, 57–62, https://doi.org/10.4161/cc.7.1.5150 (2008).
21. Strong, L. & Hollandier, W. Hereditary loop-tail in the house mouse accompanied by imperforate vagina and craniorachischisis when homozygous. J Hered 40, 329–334 (1949).
22. Yin, H., Copley, C. O., Goodrich, L. V. & Deans, M. R. Comparison of phenotypes between different vangl2 mutants demonstrates dominant effects of the Loop-tail mutation during hair cell development. PLoS One 7, e31988, https://doi.org/10.1371/journal.pone.0031988 (2012).
23. Illiescu, A., Gravel, M., Horth, C., Kibar, Z. & Gros, P. Loss of membrane targeting of Vangl proteins causes neural tube defects. Biochem J 409, 675–684, https://doi.org/10.1042/0264-6021/40905 (2007).
24. Deome, K. B., Faulkin, L. J., Jr., Bern, H. A. & Blair, P. B. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C57BL mice. Cancer Res 19, 515–520 (1959).
25. Harburg, G. et al. SLIT/ROBO2 signaling promotes mammary stem cell senescence by inhibiting Wnt signaling. Stem Cell Reports 3, 385–393, https://doi.org/10.1016/j.stemcr.2014.07.007 (2014).
26. Daniel, C. W. Finite growth span of mouse mammary gland serially propagated in vivo. Expert Rev. 29, 1422–1424 (1973).
27. Nagaoka, T. et al. The Wnt/planar cell polarity pathway component Vangl2 induces synapse formation through direct control of N-cadherin. Cell Rep 6, 916–927, https://doi.org/10.1016/j.celrep.2014.01.044 (2014).
28. Tao, H. et al. Nuclear localization of Prickle2 is required to establish cell polarity during early mouse embryogenesis. Dev Biol 364, 138–148, https://doi.org/10.1016/j.ydbio.2012.01.025 (2012).
29. Macias, H. et al. SLIT/ROBO1 signaling suppresses mammary branching morphogenesis by limiting basal cell number. Dev Cell 20, 827–840, https://doi.org/10.1016/j.devcel.2011.05.012 (2011).
30. Zhang, Y. & Levin, M. Left-right asymmetry in the chick embryo requires core planar cell polarity protein Vangl2. Genesis 47, 719–729, https://doi.org/10.1002/dvg.20551 (2009).
31. Yu, C. C., Verheyen, E. M. & Zeng, Y. A. Mammary Development and Breast Cancer: A Wnt Perspective. Cancers (Basel) 8, https://doi.org/10.3390/cancers8070656 (2016).
32. Poobalasingam, T. et al. Heterozygous Vangl2 (Looptail) mice reveal novel roles for the planar cell polarity pathway in adult lung homeostasis and repair. *Dis Model Mech* **10**, 409–423, https://doi.org/10.1242/dmm.028175 (2017).

33. Navis, A. & Bagnat, M. Apicobasal Polarity and Lumen Formation During Development. *Cell Polarity* 2: Role in Development and Disease, 67–92, https://doi.org/10.1007/978-3-319-14466-5_3 (2015).

34. Lake, B. B. & Sokol, S. Y. Strabismus regulates asymmetric cell divisions and cell fate determination in the mouse brain. *J Cell Biol* **185**, 59–66, https://doi.org/10.1083/jcb.200807073 (2009).

35. Le Grand, F., Jones, A. E., Seale, V., Scime, A. & Rudnicki, M. A. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. *Cell Stem Cell* **4**, 535–547, https://doi.org/10.1016/j.stem.2009.03.013 (2009).

36. Belotti, E. et al. Molecular characterisation of endogenous Vangl2/Vangl1 heteromeric protein complexes. *PLoS One* **7**, e46213, https://doi.org/10.1371/journal.pone.0046213 (2012).

37. Parmar, A. N. et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. *BMC Cancer* **14**, 785, https://doi.org/10.1186/s12885-014-0785 (2014).

38. Pietersen, A. M. et al. Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. *Curr Biol* **18**, 1094–1099, https://doi.org/10.1016/j.cub.2008.06.070 (2008).

39. Cui, C. J., Chen, X. & Henson, J. N. Developmental basis of severe neural tube defects in the loop-tail (Lp) mutant mouse of use of microsatellite DNA markers to identify embryonic genotype. *Dev Biol* **165**, 20–29, https://doi.org/10.1006/dbio.1994.1230 (1994).

40. Young, L. J. T. The Cleared Mammary Fat Pad and the Transplantation of Mammary Gland Morphological Structures and Cells. (Kluwer Academic/Plenum Press, 2000).

41. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nature methods* **9**, 676–682, https://doi.org/10.1038/nmeth.2019 (2012).

42. Welm, B. E., Dijkstra, G. J., Bledau, A. S., Welm, A. L. & Werb, Z. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. *Cell Stem Cell* **2**, 90–102, https://doi.org/10.1016/j.stem.2007.10.002 (2008).

43. Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models of normal and malignant breast epithelial cells. *Nature methods* **4**, 359–365, R345–356, https://doi.org/10.1530/ERC-14-0141 (2014) (2007).

Acknowledgements

We thank Jen Compton, Oscar Fernandez and Ben Abrams for technical assistance and the core support from the UCSC Institute for the Biology of Stem Cells. We also thank Santa Cruz Biotechnology for the VANGL2 antibody. We are thanked for support from the Peter MacCallum Cancer Centre Microscopy, Histology, and Animal Core Facilities, in particular assistance from Samantha Williams and Tanja Kinwell. We thank Susan Strome and Bill Saxton for allowing the use of their Solamere Spinning Disk Confocal Microscope. This work was supported by the NIH: R01 GM098897 to LH, NHGRI-R25 HG006836 pre-doctoral support to PS and to the Santa Cruz Cancer Benefit Group to LH.

Author Contributions

PS., N.G., P.H. and L.H. designed research. PS., N.G., S.R., M.T. and M.M. performed research. D.H. generated the Vangl2lox/lox allele, PS., N.G., S.R., M.T. and M.M. and L.H. analyzed data. E.V. and J.A. provided the Vangl1 CKO mice and reagents. PS., N.G. and L.H. wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43444-4.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019